Safety and efficacy profile of commercial veterinary vaccines against Rift Valley Fever disease
Moataz Sideeg Alhaj
Rift valley fever (RVF) is an infectious illness with serious clinical manifestations and health consequences in humans and a wide range of domestic ruminants. The virus transmitted either by mosquito bites or through exposure to blood, body fluids or infected animal tissues. As with other viral diseases the prevention and control of RVF relies heavily on immunization of susceptible herds with safe and cost-effective vaccine, that able to confer long-term protective immunity. Interestingly, several strains of RVF vaccines have been developed and available in commercial production. The two most prominent among these vaccines are Formalin-Inactivated vaccine, and live attenuated Smithburn vaccine. Although, both are immunogenic and widely used in control programs, they proved to be accompanied by significant concerns. The first one requires multiple doses for protection, and the other has been reported to cause abortion and fetal malformation in pregnant ewes, as well as a possible reversion to virulence. Recently, a newly described RVF vaccine registered and extensively used in South Africa and Namibia named Clone13. Safety and efficacy trials proved the vaccine as safe in pregnant ewes as highly immunogenic, along with its potential for differentiating infected from vaccinated animals(DIVA). In conclusion, with the exception of Clone13 vaccine, RVF vaccines presently available in markets are not fulfill the requirements of safety and potency. Various novel candidate vaccines against RVF are under development, presumably safer and more immunogenic than currently available in markets, have not seen the light yet. Consequently, incentive plans should be introduced to companies to bring those promising candidates to markets.